Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
05/2012
05/23/2012CN101798600B Application of SERPINE2 gene
05/23/2012CN101797381B Compound of hepatitis B virus antigen and lewis oligosaccharide and preparation method and application thereof
05/23/2012CN101724605B Foot-and-mouth disease virus (FMDV) resistant monoclonal antibody and identified epitope and application thereof
05/23/2012CN101705198B Edwardsiella tarda attenuated strain and application thereof
05/23/2012CN101679485B Osteopontin functional epitopes, monoclonal antibodies against the epitopes and uses thereof
05/23/2012CN101664549B Process for purifying antigen of foot and mouth disease vaccine
05/23/2012CN101580540B Mouse HCV (hepatitis C virus) polypeptide epitope combined with MHC-I molecule and application thereof
05/23/2012CN101475942B B19 virus VP1 unique region gene
05/23/2012CN101412984B Streptococcus suis type 2 three-component subunit vaccine and use
05/23/2012CN101406698B Dog type II adenovirus live vector recombinant vaccine for displaying protective antigen of rabies virus
05/23/2012CN101376891B Preparation of novel tuberculosis vaccine and use thereof
05/23/2012CN101376025B Bacillus tubercle gene vaccine for treating medicine-tolerant pulmonary tuberculosis
05/23/2012CN101240019B Enterorrhagia colibacillus 0157:H7 Shiga toxin 2A1 subunit active segment Stx2a1 recombination protein, expression method and application
05/23/2012CN101235083B HIV-I resisting polypeptide, coded sequence and use thereof
05/23/2012CN101199845B Stable anti-IgE humanized single anti-agent
05/23/2012CN101146518B Preparation method of chemically defined stabiliser composition
05/23/2012CN101142319B Vaccines based on the use of mv
05/22/2012US8183358 Puumala virus full-length M segment-based DNA vaccines
05/22/2012US8183354 Virus coat protein/receptor chimeras and methods of use
05/22/2012US8183352 Attenuated vif DNA immunization cassettes for genetic vaccines
05/22/2012US8183209 Treatment of T-cell mediated diseases
05/22/2012US8182996 Compositions and methods for detecting Klebsiella pneumoniae
05/22/2012US8182985 Anti-TSG101 antibodies and their uses for treatment of viral infections
05/22/2012US8182823 Compositions and methods for the therapy and diagnosis of breast cancer
05/22/2012US8182822 treating a food allergy; orally administer 100 mu g/kg or more of transforming growth factor-beta (TGF- beta ); no side effects
05/22/2012US8182821 Flu vaccine admixture of mannan and flu antigen
05/22/2012US8182820 Method for inducing cross-reactive immune responses to the human immunodeficiency virus (HIV) in a host by administering feline immunodeficiency virus (FIV) capsid (CA) or reverse transcriptase (RT) immunogens
05/22/2012US8182819 Composition and method for facilitating the internalization of a therapeutic agent into a cell
05/22/2012US8182818 Methods of using anti-TNF antibodies for treating radiation damage to the digestive tract
05/22/2012US8182817 Antibodies to human IL-22
05/22/2012US8182816 Methods of treating cancer
05/22/2012US8182815 Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatment
05/22/2012US8182813 Human C-FMS antigen binding proteins
05/22/2012US8182812 Human monoclonal antibodies against CD25
05/22/2012US8182811 Antibodies to CXCL13
05/22/2012US8182810 IL-B30 antibodies
05/22/2012US8182809 Methods for treating cancer by inhibiting MIC shedding
05/22/2012US8182805 Prevention of allergic sensitization
05/22/2012CA2660355C Polynucleotide vaccine formulation against pathologies of the horse
05/22/2012CA2492938C Cancer vaccines containing epitopes of oncofetal antigen
05/22/2012CA2464947C Combination therapy for treating disease
05/22/2012CA2458442C Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption
05/22/2012CA2436107C Kyberdrug as autovaccines with immune-regulating effects
05/22/2012CA2411949C Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
05/22/2012CA2386865C Diagnosis and therapy of cancer using sgp28-related molecules
05/22/2012CA2371977C Media in the form of complex dispersions, their process of preparation and their uses
05/22/2012CA2274803C Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily
05/18/2012WO2012065135A2 Immunomodulatory compositions, methods and systems comprising immunogenic fragments of apob100
05/18/2012WO2012065133A1 Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
05/18/2012WO2012065105A2 Chimeric flavivirus vaccines
05/18/2012WO2012065072A2 IMPROVED HIGH CONCENTRATION ANTI-TNFα ANTIBODY LIQUID FORMULATIONS
05/18/2012WO2012065055A2 Fusion proteins for hiv therapy
05/18/2012WO2012065044A2 Treating bladder tumor cells using fibronectin attachment protein as a target
05/18/2012WO2012065034A1 Enolase peptide conjugate vaccines against staphylococcus aureus
05/18/2012WO2012064842A2 System and method for generating micro-seismic events and characterizing properties of a medium with non-linear acoustic interactions
05/18/2012WO2012064836A1 Methods and compositions for neural disease immunotherapy
05/18/2012WO2012064834A2 Methods for organ regeneration
05/18/2012WO2012064816A2 Methods of neutralizing viral infection
05/18/2012WO2012064771A1 Actriia binding agents and uses thereof
05/18/2012WO2012064760A2 Materials and methods for directing an immune response to an epitope
05/18/2012WO2012064733A2 Antibody scaffold for homogenous conjugation
05/18/2012WO2012064659A1 Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
05/18/2012WO2012064627A2 Subcutaneously administered anti-il-6 receptor antibody
05/18/2012WO2012064429A2 Skin permeating and cell entering (space) peptides and methods of use thereof
05/18/2012WO2012063955A1 Therapeutic agent for arteriosclerosis or arteriosclerotic disorders and diagnostic agent for arteriosclerosis or arteriosclerotic disorders
05/18/2012WO2012063839A1 Anti single-strand type-iv collagen polypeptide antibody, and pharmaceutical, or agent for diagnosing, preventing or treating tumours, containing same
05/18/2012WO2012063212A1 North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
05/18/2012WO2012062873A2 Highly immunogenic hiv p24 sequences
05/18/2012WO2012062861A1 New adjuvant
05/18/2012WO2012062697A1 Combination therapy for type 1 diabetes
05/18/2012WO2012062694A1 Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
05/18/2012WO2012062653A1 Combination of bevacizumab and 2,2-dimethyl-n-((s)-6-oxo-6,7-dihydro - 5h-dibenzo[b,d]azepin-7-yl)-n'-(2,2,3,3,3-pentafluoro-propyl)-malonamide for the treatment of proliferative disorders
05/18/2012WO2012062596A1 Prevention of adverse effects caused by cd3 specific binding domains
05/18/2012WO2012062094A1 Conjugate of folate and antibody, preparation method and use thereof
05/18/2012WO2012061882A1 Treatment and prevention of malaria
05/18/2012WO2012032526A3 Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
05/18/2012WO2012027611A3 INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
05/18/2012WO2012025873A3 STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
05/18/2012WO2012024283A3 Universal influenza a vaccines
05/18/2012WO2012021840A3 Materials and methods for designing autologous idiotype vaccines and treatment of b-cell malignancies
05/18/2012WO2012019086A3 Inhibition of lar phosphatase to enhance therapeutic angiogenesis
05/18/2012WO2012012600A3 Peptide compounds for regulating the complement system
05/18/2012WO2012011992A3 Ricin vaccine and methods of making and using thereof
05/18/2012WO2012003320A3 Flavivirus host-range mutations and uses thereof
05/18/2012WO2011159847A3 Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
05/18/2012WO2011155705A9 Composition for inhibiting hyperlipidemia and obesity by inhibiting intestinal absorption of cholesterol
05/18/2012CA2825083A1 Conjugate of folate and antibody, preparation method and use thereof
05/18/2012CA2820590A1 Anti single-strand type-iv collagen polypeptide antibody, and pharmaceutical, or agent for diagnosing, preventing or treating tumours, containing same
05/18/2012CA2817709A1 Consensus prostate antigens, nucleic acid molecule encoding the same and vaccine and uses comprising the same
05/18/2012CA2817561A1 System and method for generating micro-seismic events and characterizing properties of a medium with non-linear acoustic interactions
05/18/2012CA2817548A1 Immunomodulatory compositions, methods and systems comprising immunogenic fragments of apob100
05/18/2012CA2817538A1 Immunomodulatory methods and systems for treatment and/or prevention of aneurysms
05/18/2012CA2817486A1 North american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
05/18/2012CA2817421A1 New adjuvant
05/18/2012CA2817418A1 Highly immunogenic hiv p24 sequences
05/18/2012CA2817219A1 Methods of treating cancer
05/18/2012CA2817216A1 Subcutaneously administered anti-il-6 receptor antibody
05/18/2012CA2817008A1 Actriia binding agents and uses thereof
05/18/2012CA2816668A1 Prevention of adverse effects caused by cd3 specific binding domains
05/18/2012CA2816593A1 Methods for organ regeneration
1 ... 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 ... 1823